These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6798690)

  • 1. Symptomatic treatment of tardive dyskinesia: a word of caution.
    Kucharski LT; Unterwald EM
    Schizophr Bull; 1981; 7(4):571-3. PubMed ID: 6798690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological modification of experimental tardive dyskinesia.
    Bárány S; Gunne LM
    Acta Pharmacol Toxicol (Copenh); 1979 Aug; 45(2):107-11. PubMed ID: 115227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current psychopathological theories of tardive dyskinesia and their implications for future research.
    Ananth J
    Neuropsychobiology; 1982; 8(4):210-22. PubMed ID: 6127649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic trials in tardive dyskinesia.
    Mackay AV; Sheppard GP
    Br J Psychiatry; 1979 Dec; 135():489-99. PubMed ID: 43753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tardive dyskinesia: I. Physiopathology and treatment].
    Andrade LA; Bertolucci PH; Pereira JS
    Arq Neuropsiquiatr; 1984 Dec; 42(4):362-70. PubMed ID: 6152578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physiopathology and curative treatment of tardive dyskinesia].
    Wolf MA; Gautier J
    Encephale; 1987; 13(5):301-8. PubMed ID: 2892663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M; Friedhoff AJ; Diamond F
    Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa and receptor sensitivity modification in tardive dyskinesia.
    Casey DE; Gerlach J; Bjørndal N
    Psychopharmacology (Berl); 1982; 78(1):89-92. PubMed ID: 6128757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Goetz CG; Klawans HL; Carvey P
    Mod Probl Pharmacopsychiatry; 1983; 21():5-20. PubMed ID: 6140633
    [No Abstract]   [Full Text] [Related]  

  • 13. Tardive dyskinesia: review and update.
    Klawans HL; Goetz CG; Perlik S
    Am J Psychiatry; 1980 Aug; 137(8):900-8. PubMed ID: 6106395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
    Friedhoff AJ; Rosengarten H; Bonnet K
    Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacologic studies of tardive dyskinesia.
    Chase TN; Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 24():457-61. PubMed ID: 7405673
    [No Abstract]   [Full Text] [Related]  

  • 16. GABA dysfunction in the pathophysiology of tardive dyskinesia.
    Tamminga CA; Thaker GK; Chase TN
    Psychopharmacology Suppl; 1985; 2():122-7. PubMed ID: 2987903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia and essential fatty acids.
    Vaddadi K; Hakansson K; Clifford J; Waddington J
    Int Rev Psychiatry; 2006 Apr; 18(2):133-43. PubMed ID: 16777667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.
    Scheel-Krüger J; Arnt J
    Psychopharmacology Suppl; 1985; 2():46-57. PubMed ID: 2987907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia: nondopaminergic treatment approaches.
    Casey DE
    Psychopharmacology Suppl; 1985; 2():137-44. PubMed ID: 2860657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Ringwald E
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.